Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v3.20.2
Subsequent Events (Details) - Subsequent event - Licensing agreements for development and commercialization
$ in Millions
Aug. 07, 2020
USD ($)
Subsequent Event  
Milestone payment upon regulatory approval in China $ 3.0
Maximum  
Subsequent Event  
Time period for scheduling by the U.S. Drug Enforcement Administration. 90 days